Esophageal carcinoma (squamous + adeno) · line 2 · Nivolumab monotherapy — 2L esophageal squamous (ATTRACTION-3)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-NIVO-MONO-ESOPH-2L |
| ID | IND-ESOPH-METASTATIC-2L-NIVO-SQUAMOUS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-ESOPHAGEAL |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
STUB — pending Co-Lead sign-off. Standard-track 2L for metastatic ESCC. UA: nivolumab not NSZU-reimbursed for esophageal — out-of-pocket / charitable. Single-agent paclitaxel weekly (or docetaxel) is the funded fallback when ICI access unavailable.
Used By
Algorithms
ALGO-ESOPH-2L- ALGO-ESOPH-2L